Prostate Cancer - Results from #1580

The Impact of Nutrient Supply on Prostate Cancer Risk Worldwide. December 27, 2023

Outcomes in patients with high- and very high-risk localized prostate cancer treated with definitive IMRT and long-term hormone therapy. December 27, 2023

Evaluation of Recurrent Disease after Radiation Therapy for Patients Considering Local Salvage Therapy: Past vs. Contemporary Management. December 26, 2023

What are the Most Important Objectives of Patients Undergoing Radical Prostatectomy? A Narrative Review. December 26, 2023

Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. December 26, 2023

A Chance Finding of High Grade Prostate Cancer in a 35-Year-Old Male - A Case Report and Outcomes of Robotic Radical Prostatectomy in Young Men with Prostate Cancer. December 26, 2023

Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer. December 26, 2023

Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer. December 26, 2023

ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers. December 26, 2023

Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer. December 26, 2023

First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer. December 25, 2023

Prevalence of bilateral loco-regional spread in unilateral pelvic PSMA PET positive recurrent prostate cancer. December 25, 2023

Blood-based liquid biopsy in advanced prostate cancer. December 25, 2023

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study. December 25, 2023

Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment. December 25, 2023

First patient dosed in Clarity’s registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA December 22, 2023

Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits. December 22, 2023

Characterizing Referrals for Prostate Cancer Genetic Services in a Safety-Net Hospital. December 22, 2023

Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. December 22, 2023

The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer. December 22, 2023

Page 80 of 1435